tbuckley/cabot-search huggingface dataset:
Novel hybrid biocomposites for tendon grafts: The addition of silk to polydioxanone and poly(lactide-co-caprolactone) enhances material properties, in vitro and in vivo biocompatibility
Authors: Behzad Shiroud Heidari, Emma Muiños Lopez, Emma Harrington, Rui Ruan, Peilin Chen, Seyed Mohammad Davachi, Benjamin Allardyce, Rangam Rajkhowa, Rodney Dilley, Froilán Granero-Moltó, Elena M. De-Juan-Pardo, Minghao Zheng, Barry Doyle
Journal: Bioactive Materials (2023)

Biopolymers play a critical role as scaffolds used in tendon and ligament (TL) regeneration. Although advanced biopolymer materials have been proposed with optimised mechanical properties, biocompatibility, degradation, and processability, it is still challenging to find the right balance between these properties. Here, we aim to develop novel hybrid biocomposites based on poly(p-dioxanone) (PDO), poly(lactide-co-caprolactone) (LCL) and silk to produce high-performance grafts suitable for TL tissue repair. Biocomposites containing 1-15% of silk were studied through a range of characterisation techniques. We then explored biocompatibility through in vitro and in vivo studies using a mouse model. We found that adding up to 5% silk increases the tensile properties, degradation rate and miscibility between PDO and LCL phases without agglomeration of silk inside the composites. Furthermore, addition of silk increases surface roughness and hydrophilicity. In vitro experiments show that the silk improved attachment of tendon-derived stem cells and proliferation over 72 h, while in vivo studies indicate that the silk can reduce the expression of pro-inflammatory cytokines after six weeks of implantation. Finally, we selected a promising biocomposite and created a prototype TL graft based on extruded fibres. We found that the tensile properties of both individual fibres and braided grafts could be suitable for anterior cruciate ligament (ACL) repair applications.
Cyberattacks hold up India’s push for digitisation of health
Authors: Shefali Malhotra
Journal: BMJ (2023)

A massive cyberattack at India's largest public hospital is raising questions about not only the targeted institution's security but the digitisation of the country's healthcare system. <b><i>Shefali</i></b><i></i><b><i>Malhotra</i></b> reports
A Review of Parallel Transmit Arrays for Ultra-High Field MR Imaging
Authors: Chang-Hoon Choi, Andrew Webb, Stephan Orzada, Mikheil Kelenjeridze, N. Jon Shah, Jörg Felder
Journal: IEEE Reviews in Biomedical Engineering (2023)

Parallel transmission (pTX) techniques are required to tackle a number of challenges, e.g., the inhomogeneous distribution of the transmit field and elevated specific absorption rate (SAR), in ultra-high field (UHF) MR imaging. Additionally, they offer multiple degrees of freedom to create temporally- and spatially-tailored transverse magnetization. Given the increasing availability of MRI systems at 7 T and above, it is anticipated that interest in pTX applications will grow accordingly. One of the key components in MR systems capable of pTX is the design of the transmit array, as this has a major impact on performance in terms of power requirements, SAR and RF pulse design. While several reviews on pTX pulse design and the clinical applicability of UHF exist, there is currently no systematic review of pTX transmit/transceiver coils and their associated performance. In this article, we analyze transmit array concepts to determine the strengths and weaknesses of different types of design. We systematically review the different types of individual antennas employed for UHF, their combination into pTX arrays, and methods to decouple the individual elements. We also reiterate figures-of-merit (FoMs) frequently employed to describe the performance of pTX arrays and summarize published array designs in terms of these FoMs.
Infection induces tissue-resident memory NK cells that safeguard tissue health
Authors: Iona S. Schuster, Xavier Y.X. Sng, Colleen M. Lau, David R. Powell, Orr-El Weizman, Peter Fleming, Georgia E.G. Neate, Valentina Voigt, Sam Sheppard, Andreas I. Maraskovsky, Sheridan Daly, Motoko Koyama, Geoffrey R. Hill, Stephen J. Turner, Timothy E. O’Sullivan, Joseph C. Sun, Christopher E. Andoniou, Mariapia A. Degli-Esposti
Journal: Immunity (2023)
Bortezomib-Dexamethasone, Rituximab, and Cyclophosphamide as First-Line Treatment for Waldenström's Macroglobulinemia: A Prospectively Randomized Trial of the European Consortium for Waldenström's Macroglobulinemia
Authors: Christian Buske, Meletios A. Dimopoulos, Alexander Grunenberg, Efstathios Kastritis, Cecile Tomowiak, Béatrice Mahé, Xavier Troussard, Roman Hajek, Andreas Viardot, Olivier Tournilhac, Therese Aurran, Stephane Lepretre, Hacene Zerazhi, Benedicte Hivert, Veronique Leblond, Sophie de Guibert, Lena Brandefors, Ramon Garcia-Sanz, Maria Gomes da Silva, Eva Kimby, Birgit Schmelzle, Dajana Kaszynski, Jens Dreyhaupt, Rainer Muche, Pierre Morel
Journal: Journal of Clinical Oncology (2023)

Rituximab/chemotherapy is a cornerstone of treatment for Waldenström's macroglobulinemia (WM). In addition, bortezomib has shown significant activity in WM. This study evaluated the efficacy and safety of dexamethasone, rituximab, and cyclophosphamide (DRC) as first-line treatment in WM.In this European study, treatment-naïve patients were randomly assigned to DRC or bortezomib-DRC B-DRC for six cycles. The primary end point was progression-free survival. Secondary end points included response rates, overall survival, and safety.Two hundred four patients were registered. After a median follow-up of 27.5 months, the estimated 24-month progression-free survival was 80.6% (95% CI, 69.5 to 88.0) for B-DRC and 72.8% (95% CI, 61.3 to 81.3) for DRC (P = .32). At the end of treatment, B-DRC and DRC induced major responses in 80.6% versus 69.9% and a complete response/very good partial response in 17.2% versus 9.6% of patients, respectively. The median time to first response was shorter for B-DRC with 3.0 (95% CI, 2.8 to 3.2) versus 5.5 (95% CI, 2.9 to 5.8) months for DRC. This resulted in higher major response rates (57.0% v 32.5%; P < .01) after three cycles of B-DRC compared with DRC. At best response, the complete response/very good partial response increased to 32.6% for B-DRC. Both treatments were well tolerated: grade ≥ 3 adverse events occurred in 49.2% of all patients (B-DRC, 49.5%; DRC, 49.0%). Peripheral sensory neuropathy grade 3 occurred in two patients treated with B-DRC and in none with DRC.This large randomized study illustrates that B-DRC is highly effective and well tolerated in WM. The data demonstrate that fixed duration immunochemotherapy remains an important pillar in the clinical management of WM.
Reply to H.S. Hochster
Authors: Daniel L. Hertz
Journal: Journal of Clinical Oncology (2023)

Dr Hochster 1 raises concerns about my recommending DPYD genetic testing before fluoropyrimidine treatment. 2He points out that the proposed DPYDguided dosing recommendations were not evaluated for efficacy in prospective randomized trials.As I noted in my article, direct efficacy comparisons in randomized trials may be unethical, implausible, and unnecessary.There is compelling evidence that DPYD-guided doses normalize systemic drug concentrations and toxicity risk and are well-calibrated to maximum tolerated doses.Additionally, the recommended starting doses are meant to be escalated as tolerated, ensuring that all patients receive maximally safe and effective treatment.Finally, I explained that if direct efficacy comparisons are necessary, these could be made within nonrandomized trials or by use of real-world data. 2
Comparing Short- and Long-Term Treatment Duration of Bevacizumab for Advanced Ovarian Cancer
Authors: Ryan Sun, Bo Huang, Lee-Jen Wei
Journal: Journal of Clinical Oncology (2023)

Pfisterer et al 1 conducted an important study to compare standard versus extended duration of bevacizumab treatment in combination with frontline chemotherapy in women with newly diagnosed stage IIB-IV ovarian cancer.Patients were randomly assigned 1:1 to receive bevacizumab for either 15 months (T15) or 30 months (T30).The primary end point was investigator-assessed progressionfree survival (PFS) for this open-label trial.There was no significant difference in PFS between treatment arms (hazard ratio [HR], 0.99; 95% CI, 0.85 to 1.15).Although the results from the study are neutral, there are a few lessons we may learn that can benefit future trials with similar settings.
Preclinical-to-Clinical Anti-Cancer Drug Response Prediction and Biomarker Identification Using TINDL
Authors: David Earl Hostallero, Lixuan Wei, Liewei Wang, Junmei Cairns, Amin Emad
Journal: Genomics Proteomics & Bioinformatics (2023)

Abstract Prediction of the response of cancer patients to different treatments and identification of biomarkers of drug response are two major goals of individualized medicine. Here, we developed a deep learning framework called TINDL, completely trained on preclinical cancer cell lines (CCLs), to predict the response of cancer patients to different treatments. TINDL utilizes a tissue-informed normalization to account for the tissue type and cancer type of the tumors and to reduce the statistical discrepancies between CCLs and patient tumors. Moreover, by making the deep learning black box interpretable, this model identifies a small set of genes whose expression levels are predictive of drug response in the trained model, enabling identification of biomarkers of drug response. Using data from two large databases of CCLs and cancer tumors, we showed that this model can distinguish between sensitive and resistant tumors for 10 (out of 14) drugs, outperforming various other machine learning models. In addition, our small interfering RNA (siRNA) knockdown experiments on 10 genes identified by this model for one of the drugs (tamoxifen) confirmed that tamoxifen sensitivity is substantially influenced by all of these genes in MCF7 cells, and seven of these genes in T47D cells. Furthermore, genes implicated for multiple drugs pointed to shared mechanism of action among drugs and suggested several important signaling pathways. In summary, this study provides a powerful deep learning framework for prediction of drug response and identification of biomarkers of drug response in cancer. The code can be accessed at https://github.com/ddhostallero/tindl.
Online cognitive behavioural therapy for post-traumatic stress disorder is as effective as face-to-face therapy
Authors: Helen Saul, Samantha Cassidy, Brendan Deeney, Jemma Kwint, Jonathan Bisson
Journal: BMJ (2023)

The studyBisson JI, Ariti C, Cullen K, et al. Guided, internet based, cognitive behavioural therapy for post-traumatic stress disorder: pragmatic, multicentre, randomised controlled non-inferiority trial (RAPID). BMJ 2022;377:e069405.To read the full NIHR Alert, go to: https://evidence.nihr.ac.uk/alert/online-cbt-for-ptsd-is-as-effective-as-face-to-face-therapy/.
Negative predictive value of prostate MRI in real world practice: Results from a statewide surgical collaborative in the United States
Authors: A. Zhu, A. Srivastava, J.M. Dibianco, J. Qi, A. Dhir, M. Maruf, S. Ferrante, A. Johnson, A. Semerjian, M.S. Davenport, L. Mammen, A. Dabaja, B. Lane, K. Ginsburg, K. Witzke, A. George
Journal: European Urology (2023)
Transition from Acute Kidney Injury (AKI) to Acute Kidney Disease (AKD) after Robot Assisted Partial Nephrectomy (RAPN): Results from a single tertiary referral centre
Authors: F. Di Maida, L. Lambertini, F. Valastro, A. Cadenar, A.A. Grosso, M. Bacchiani, S. Giudici, A. Mari, A. Minervini
Journal: European Urology (2023)
Radical therapy for low-risk upper tract urothelial carcinoma (ROBUUST collaborative group)
Authors: N. Corsi, S. Pandolfo, B.M. Eilender, S.H. Bell, L. Wang, G. Tuderti, A. Ghoreifi, M. Tozzi, J. Taylor, S. Dhanji, C. Yong, E. Checcucci, I.H. Derweesh, D.D. Eun, F. Porpiglia, M.L. Gonzalgo, R. Mehrazin, G. Simone, M. Ferro, V. Margulis, C.P. Sundaram, H. Djaladat, Z. Wu, R. Autorino, F. Abdollah
Journal: European Urology (2023)
A new machine learning model to predict Novel Trifecta achievement and validation of its prognostic significance in a large single centre series of minimally invasive partial nephrectomy
Authors: A. Uleri, M. Baboudjian, J. Gaya, R. Oscar, A. Rosales, A. Gallioli, A. Territo, J. Robalino, M. Casadevalls, A. Farré, G. Basile, P. Verri, J. Palou, A. Breda
Journal: European Urology (2023)
Ex vivo Fluorescence Confocal Microscopy (FCM) of Perineal Prostate Biopsies (PPB) allows fast-track examination of MRI-guided targeted biopsies in routine diagnostics
Authors: K-D. Sievert, T. Hansen, B. Titze, B. Schulz, A. Omran, F. Abd Ali, U. Titze
Journal: European Urology (2023)
Estimating postoperative renal function after surgery for nonmetastatic renal masses: A systematic review of available prediction models
Authors: A. Pecoraro, R. Campi, R. Bertolo, M. Mir, M. Marchioni, S. Serni, S. Joniau, H. Van Poppel, M. Albersen, E. Roussel
Journal: European Urology (2023)
Comparing the use of AquaBeam® and HoLEP for the treatment of patients with benign prostatic hyperplasia
Authors: C. Toribio-Vazquez, R. Cansino, E. Fernández-Pascual, A. Eguibar, H. Ayllon, P. Solano-Heranz, J.R. Perez-Carral, J.A. Mainez, M. Giron, A. Rodriguez, A. Yebes, M. Alonso, S. Martínez, L. Martínez-Piñeiro
Journal: European Urology (2023)
Feasibility and safety of full retroperitoneoscopic radical nephroureterectomy: A single-center experience
Authors: A. Marquis, F. Soria, M. Oderda, M. Allasia, P. Destefanis, S. Livoti, M. Rosazza, D. Dutto, B. Lillaz, P. Gontero
Journal: European Urology (2023)
Robot assisted radical prostatectomy performed with the novel surgical robotic platform HugoTM RAS: Initial experience and perioperative outcomes at a tertiary referral robotic center
Authors: M. Campetella, R. Bientinesi, C. Gandi, A. Totaro, G. Palermo, F. Gavi, E. Scarciglia, F. Marino, P. Bassi, E. Sacco
Journal: European Urology (2023)
Surgical and functional outcomes of penile prosthesis implantation in men with neurological conditions
Authors: M. Falcone, P. Capogrosso, L. Cirigliano, M. Preto, M. Timpano, F. Peretti, I. Ferro, N. Plamadeala, N. Schifano, C. Ceruti, F. Giorgio, C. Bettocchi, T. Cai, A. Vitarelli, M. Carrino, M. Paradiso, E. Pescatori, F. Colombo, E. Caraceni, F. Dehò, A. Palmieri, P. Gontero
Journal: European Urology (2023)
Salvage vesiculectomy for local prostate cancer recurrence: surgical technique, complications and early postoperative outcomes
Authors: A. Giesen, T. Van Den Broeck, D. Develtere, D. Pfister, S. Langley, R. Hente, M. Claessens, Y. Raskin, C. Eden, R.J. Karnes, K. Wymer, A. Heidenreich, S. Joniau
Journal: European Urology (2023)
A dedicated screening for early detection of prostate cancer in men with germline mutations in DNA-repair genes
Authors: G. Chiarelli, V. Fasulo, M. Zuradelli, P. Arena, E. Beatrici, A. Gobbo, C. Saitta, R. Hurle, A. Saita, F. Maura, R. Asselta, G. Soldà, P. Casale, G. Guazzoni, G. Lughezzani, N. Buffi, M. Lazzeri
Journal: European Urology (2023)
Robotic pyelo-ureterostomy to native ureter to solve urinary tract stricture after kidney transplantation: Step by step
Authors: F. Vigués Julià, B. Etcheverry Giadrosich, P. Sanz-Serra, A. Abella Serra, J.F. Suárez Novo, L. Riera Canals, M. Castells Esteve
Journal: European Urology (2023)
Identifying candidates for one-night stay robot assisted simple prostatectomy: Single center analysis
Authors: A.M. Bove, A. Brassetti, U. Anceschi, S. D’Annunzio, M.C. Ferriero, R. Mastroianni, G. Tuderti, L. Misuraca, A. Iannuzzi, F. Prata, A. Ragusa, M. Gallucci, G. Simone
Journal: European Urology (2023)
Bone metastasis enrichment factor SHMT2 promotes prostate cancer metastasis and affects immune infiltration through Akt/β-catenin signaling pathway
Authors: L. Yiming, Z. Haitao, P. Shengmeng, T. Chen, L. Zhen, C. Yongming, W. Wanhua, L. Lingfeng, Z. Jie, H. Huang, G. Zhenghui
Journal: European Urology (2023)
The management of adult male anterior urethral strictures in low and middle income countries. Results from a Pan-African survey on male anterior urethral stricture management among urologists (PASUSM)
Authors: A. Mellouki, O.J.D. Ziba, K.H. Gebreselassie, S.A. Nedjim, A. Afolayan, Y.J.R.P. Traore, B. Kirakoya, A. Ouattara, F.A. Kaboré, S. Mellas, J.E. El Ammari, M.F. Tazi, M.J. El Fassi, M. Kura, M.H. Farih
Journal: European Urology (2023)
Retrocaval ureter: Robot assisted ureterolithotomy and ureteral transposition
Authors: M. Matinero Tor, M. Riera Ponsatí, A. Marfany Pluchart, J. Peña Lueza, M.V. Muñoz Rivero, C.A. Estigarribia Benitez, M. Palomera Fernández, G.S. Velez Guayasamin, X. Pascual Garcia, J.M. Auguet Martín, J.R. Bordalba Gómez
Journal: European Urology (2023)
Novel trial designs in localised prostate cancer: Pilot phase results from the prostate pathway embedded comparative trial (ip3-prospect)
Authors: E.J. Bass, F. Fiorentino, M. Szigeti, N. Klimowska-Nassar, T. Sasikaran, P. Jadav, F. Rawlins, M. Oblak, B. Khoubehi, M. Winkler, M. Nasseri, A. Pope, H. Sokhi, T. Dudderidge, N. Arumainayagam, M.R. Sydes, H.U. Ahmed
Journal: European Urology (2023)
Kidney transplantation from donation after brain death versus donation after circulatory death using abdominal normothermic oxygenated circulation: Is there a difference in surgical complications?
Authors: A. Costa Silva, T. Pina-Vaz, M. Manso, T. Antunes-Lopes, M. Pestana, M. Rios, C. Martins-Silva, A. Morgado, J. Silva
Journal: European Urology (2023)
Salvage vesiculectomy for local prostate cancer recurrence: PSA response and oncological outcomes
Authors: A. Giesen, T. Van Den Broeck, D. Pfister, D. Develtere, K. Wymer, S. Langley, R. Hente, M. Claessens, C. Eden, A. Heidenreich, R.J. Karnes, Y. Raskin, S. Joniau
Journal: European Urology (2023)
Ejaculation preservation in patients with benign prostatic obstruction: The safety and efficacy of transperineal interstitial laser ablation
Authors: F. Sessa, A. Rivetti, P. Polverino, M. Lo Re, C. Bisegna, M. Saladino, G. Siena, A. Cocci, A. Pecoraro, R. Campi, A. Minervini, S. Serni
Journal: European Urology (2023)
DEPROMP Trial: The additive value of PSMA-PET/CT-guided biopsy for prostate cancer management in biopsy naïve men
Authors: P. Krausewitz, F.C. Gärtner, M. Essler, U. Attenberger, J. Luetkens, G. Kristiansen, C.H. Ohlmann, S. Hauser, J. Ellinger, M. Ritter
Journal: European Urology (2023)
Personalized bedtime determined by a wearable device improves nocturia; A prospective interventional crossover study
Authors: Y. Okumura, S. Nobukawa, T. Ishibashi, T. Takahashi, M. Katsuki, T. Kakitsuba, N. Tanaka, Y. Fukiage, T. Kabuto, H. Kobayashi, M. Tsutsumiuchi, T. Shinagawa, M. Seki, S. Inamura, M. Taga, M. Fukushima, H. Kosaka, O. Yokoyama, N. Terada
Journal: European Urology (2023)
Is the Urolift a fertility sparing technique in patients suffered from BPH?
Authors: N. d’Altilia, P. Annese, V. Mancini, U.G. Falagario, E. Tocci, F. Cinelli, M. Finati, L. Martino, G.M. Busetto, C. Bettocchi, G. Carrieri
Journal: European Urology (2023)
The insula, a key brain area for bladder pain control, is modulated by stress
Authors: M. Santos-Pereira, S. Silva, L. Santos-Leite, A.I. Silva, A.F. Terceiro, C. Pinto, T. Canedo, F. Monteiro, T. Summavielle, K. Vicent, R. Treede, J. Nagel, M. Merlos, F. Cruz, A. Charrua
Journal: European Urology (2023)
Development and validation of a clinical nomogram predicting detrusor underactivity via symptoms and noninvasive test parameters in men with benign prostatic hyperplasia
Authors: Y. Wu, K. Lv, B. Zheng, X. Hao, W. Lai, X. Xia, G. Yang, S. Huang, Z. Luo, G. Yang, C. Lv, Z. An, W. Peng, T. Song, Q. Yuan
Journal: European Urology (2023)
Impact of renal sinus protrusion morphology of tumors on achieving trifecta in robot-assisted partial nephrectomy
Authors: Y. Hattori, A. Nagoshi, T. Fujiwara, T. Kambe, Y. Mine, H. Hagimoto, Y. Abe, D. Yamashita, N. Tsutsumi, S. Arizono, N. Shibasaki, T. Yamasaki, M. Kawakita
Journal: European Urology (2023)
Concordance of renal sinus or calyces invasion between preoperative imaging and final pathology after surgery for kidney cancer
Authors: F. Cei, N. Tenace, G. Basile, G. Musso, C. Re, G. Fallara, G. Rosiello, F. Belladelli, D. Cignoli, D. Canibus, I. Rowe, F. De Cobelli, G. Brembilla, R. Pennella, A. Della Corte, G. Guazzarotti, R. Bertini, A. Briganti, M. Colecchia, F. Montorsi, A. Salonia, A. Larcher, R. Lucianò, U. Capitanio
Journal: European Urology (2023)
Progression of high-risk non-muscle invasive bladder cancer correlates with immune phenotypes and Fibroblast Activation Protein-α (FAP)
Authors: T. Muilwijk, L. Baekelandt, M. Akand, S. Daelemans, K. Marien, Y. Waumans, P-J. Van Dam, T. Van Den Broeck, B. Van Cleynenbreugel, F. Van Der Aa, T. Gevaert, S. Joniau
Journal: European Urology (2023)
12 months clinical outcomes of Transurethral UltraSound Ablation (TULSA) for benign prostatic hyperplasia
Authors: M.H.J. Anttinen, A. Viitala, P. Doerwald, P. Mäkelä, P. Nurminen, H. Pärssinen, T. Sainio, I. Virtanen, P. Taimen, R. Blanco Sequeiros, P.J. Boström
Journal: European Urology (2023)
Artificial intelligence to improve cytology performance in bladder urothelial carcinoma diagnosis: Results of the French, multicenter, prospective VISIOCYT1 trial
Authors: T. Lebret, X. Paoletti, G. Pignot, M. Roumiguié, M. Colombel, L. Savareux, G. Verhoest, L. Guy, J. Rigaud, S. De Vergie, G. Poinas, S. Droupy, F. Kleinclauss, M. Courtade-Saidi, E. Piaton, C. Radulescu, N. Rioux-Leclercq, K. Renaudin, C. Kandel-Aznar, B. Cochand-Priollet, Y. Allory, M. Rouprêt
Journal: European Urology (2023)
ReIMAGINE Prostate Cancer Risk: A prospective cohort study in men with a suspicion of prostate cancer who are referred onto an MRI-based diagnostic pathway with donation of tissue, blood, urine and imaging for biomarker analyses
Authors: H.U. Ahmed, E. Frangou, T. Marsden, C. Moore, P. Shonit, P. Singh, C. Brew-Graves, R. Clow, A. Freeman, J. Hadley, F. Rawlins, A. Santaolalla, M. Rodriguez-Justo, T. Syer, S. Tuck, A. Wingate, M. Van Hemelrijk, G. Attard, L. Brown, M. Emberton
Journal: European Urology (2023)
External validation of a nomogram for the prediction of an intervention for bleeding control after renal trauma
Authors: T.S. Schmidli, S. Sigg, S. Keihani, L. Bosshard, M. Prummer, A.S. Nowag, J. Birzele, C. Zhang, J.B. Myers, R.T. Strebel
Journal: European Urology (2023)
Non-seminomatous testicular germ cell tumours with teratoma-free primaries exhibit a superior early relapse-free survival
Authors: P. Paffenholz, G. Landwehr, C. Seidel, A. Poch, C. Bokemeyer, R. Cathomas, P. Pongratanakul, A. Hiester, P. Albers, M. Pichler, S. Krege, I. Syring-Schmandke, J. Heinzelbecker, T. Nestler, D. Pfister, A. Heidenreich
Journal: European Urology (2023)
Bacillus calmette-guerin vs immediate radical cystectomy in eau defined very high-risk non-muscle invasive bladder cancer patients
Authors: R. Contieri, P. Hensley, V. Grajales, W.S. Tan, K. Bree, C.C. Guo, G.M. Nogueras-Gonzalez, N. Navai, C.P. Dinney, A.M. Kamat
Journal: European Urology (2023)
Three-dimensional prostate model use and augmented reality guided frozen section analysis during robot-assisted radical prostatectomy
Authors: S. Luzzago, F.A. Mistretta, M.L. Piccinelli, G. Marvaso, M. Nizzardo, S. Nardini, G. Cozzi, A. Brescia, M. Ferro, B.A. Jereczek-Fossa, G. Musi, O. De Cobelli
Journal: European Urology (2023)
New minimally invasive techniques versus turp for middle volume (30-80 ml) prostates: A prospective randomized study
Authors: A.L. Pastore, O.A. Rera, A. Fuschi, A. Martoccia, Y. Al Salhi, C. De Nunzio, A. Cicione, A. Sciarra, S. Salciccia, C. Leonardo, F. Proietti, A. Carbone
Journal: European Urology (2023)
Initial clinical trial of focal laser ablation utilising ProFocal-Rx™ for localised prostate cancer
Authors: J. Kam, G. Mcclintock, B. Hanna, S. Jackson, J. Makary, A. Grant, J. Rahkala, M. Arianayagam, B. Canagasingham, R. Ferguson, A. Goolam, N. Jeffery, M. Winter, M. Khadra, R. Ko, N. Mehan, I. Thangasamy, C. Varol
Journal: European Urology (2023)